<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03693703</url>
  </required_header>
  <id_info>
    <org_study_id>bpMRscr16</org_study_id>
    <nct_id>NCT03693703</nct_id>
  </id_info>
  <brief_title>Comparison of Multi-parametric and Bi-parametric Magnetic Resonance Imaging in Men With Suspicion of Prostate Cancer</brief_title>
  <official_title>Cost-efficacy of a Preliminary Diagnostic Program Using Bi-parametric Magnetic Resonance Imaging in Men With Suspicion of Prostate Cancer and no Previous Prostate Biopsy: a Prospective Randomized Clinical Study Comparing Multiparametric and Bi-parametric Magnetic Resonance Imaging Results</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione del Piemonte per l'Oncologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione del Piemonte per l'Oncologia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the detection rate of biparametric (bp) magnetic resonance imaging (MRI) for&#xD;
      clinically significant prostate cancer (PCa) with that of multiparametric (mp)-MRI, in&#xD;
      biopsy-naïve patients. Today, bp-MRI is not the standard diagnostic procedure, however&#xD;
      preliminary studies showed its non-inferiority with respect to mp-MRI. Its implementation on&#xD;
      a wide scale could significantly reduce examination costs (no iv contrast agent and no&#xD;
      endorectal coil), and study time.&#xD;
&#xD;
      Secondary objectives will be:&#xD;
&#xD;
        -  to assess specificity of a blood test based on microRNA (miR) score in biopsy-naïve&#xD;
           patients, using pathological assessment after MR-guided biopsy as reference standard. If&#xD;
           specificity of the miR score is higher than that of PSA, then fewer patients will&#xD;
           undergo unnecessary MRI, thus increasing the efficiency of the diagnostic pipeline for&#xD;
           PCa;&#xD;
&#xD;
        -  to develop a clinical decision support system (CDSS) based on MRI and circulating miR&#xD;
           evaluation, to stratify patients according to their risk of PCa progression, using&#xD;
           pathological assessment after prostatectomy as reference standard. Patients will be&#xD;
           stratified into two classes of risk: i) low-risk PCa, in which patients may benefit from&#xD;
           a conservative approach (i.e. active surveillance), and ii) medium/high-risk PCa in&#xD;
           which patients should undergo radical treatment (i.e. surgery or radiation therapy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is a prospective, randomized, two-arms study with a 2:1 ratio. Subjects meeting the&#xD;
      inclusion criteria will be randomized either into the bp-MRI group (arm A), or the mp-MRI one&#xD;
      (arm B). All subjects will perform blood sampling in EDTA tubes before undergoing imaging&#xD;
      session. Plasma will be isolated within 1 hour from sampling, with a double round&#xD;
      centrifugation, aliquoted and stored at -80°C before undergoing miR analysis.&#xD;
&#xD;
      MRI will be performed with a 1.5 T using axial T2w and diffusion-weighted imaging for&#xD;
      subjects in arm A with no endorectal coil and no intravenous contrast agent. Men randomized&#xD;
      in arm B will undergo MRI with T2w in the three acquisition planes, diffusion-weighted and&#xD;
      dynamic contrast-enhanced imaging usign endorectal coil.&#xD;
&#xD;
      Random biopsy will be performed in subjects with no suspicious regions for PCa found on MRI.&#xD;
      Men with suspicious regions on MRI will be invited to a targeted or in-bore biopsy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2018</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate of bi-parametric MRI, and of mp-MRI in men at risk for PCa and with no previous prostate biopsy</measure>
    <time_frame>3 months</time_frame>
    <description>Sensitivity, specificity, PPV and NPV will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dimension of lesions identified at bp-MRI/mp-MRI;</measure>
    <time_frame>2 weeks</time_frame>
    <description>Mean lesion dimension will be assessed in each study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of clinically significant PCa identified at bp-MRI;</measure>
    <time_frame>2 weeks</time_frame>
    <description>The number of clinically significant PCa over the total number of PCa detected at bp-MRI will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of miR test alone and in combination with PSA blood test in identifying histologically confirmed PCa patients</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">391</enrollment>
  <condition>Prostatic Neoplasm</condition>
  <arm_group>
    <arm_group_label>bi-parametric MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo axial T2-weighted and diffusion-weighted imaging (no contrast agent injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multi-parametric MRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo multiparametric MRI including morphological study (T2- and T1-weighted imaging) and functional acquisitions (diffusion-weighted and dynamic contrast-enhanced imaging)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>bi-parametric MRI</intervention_name>
    <description>Axial T2-weighted and diffusion-weighted imaging with no endorectal coil nor intravenous contrast agent administration</description>
    <arm_group_label>bi-parametric MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>multi-parametric MRI</intervention_name>
    <description>T2-weighted imaging in the three planes, diffusion-weighted and dynamic contrast-enhanced imaging using endorectal coil and intravenous contrast agent administration</description>
    <arm_group_label>multi-parametric MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &lt;= 75 years&#xD;
&#xD;
          -  PSA &lt;= 15 ng/ml&#xD;
&#xD;
          -  no previous prostate biopsy&#xD;
&#xD;
          -  negative digital rectal examination&#xD;
&#xD;
          -  signed infomed conset&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known prostate cancer diagnosis&#xD;
&#xD;
          -  previous prostate biopsy or surgery&#xD;
&#xD;
          -  contraindication to MRI&#xD;
&#xD;
          -  non-cooperative subjects&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo Russo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione del Piemonte per l'Oncologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia - Candiolo Cancer Institute</name>
      <address>
        <city>Candiolo</city>
        <state>Turin</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>prostate biopsy</keyword>
  <keyword>microRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

